Examining the Long-term Clinical Evidence of Therapies for Inflammatory Bowel Disease in Bio-naïve Patients - Episode 1
Overview of IBD
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).
Transcript
David Hudesman, MD: Hello, and welcome to this HCPLive® Peer Exchange titled “Examining the Long-term Clinical Evidence of Therapies for Inflammatory Bowel Disease in Bio-Naïve patients.” I’m Dr David Hudesman, a codirector of the Inflammatory Bowel Disease Center at NYU Langone Health in New York. Joining me today is a great group of people.
Millie Long, MD, MPH: Hi, I’m Millie Long from University of North Carolina at Chapel Hill.
Anita Afzali, MD: Hi, I’m Anita Afzali from the University of Cincinnati [in Ohio].
Maia Kayal, MD: I’m Maia Kayal, an assistant professor at the Icahn School of Medicine in New York.
Miguel Regueiro, MD: Hi, I’m Miguel Regueiro from the Cleveland Clinic [in Ohio].
David Hudesman, MD: Our discussion will focus on the current understanding of the effectiveness and safety of different therapies for Crohn [disease] and ulcerative colitis [UC]. We’ll also explore different treatment approaches with biologics and nonbiologic therapies to improve patient outcomes in UC and Crohn disease. Welcome, everyone. Let’s jump right in. Anita, start by giving us the treatment landscape. What are our therapeutic options for patients with Crohn and ulcerative colitis?
Anita Afzali, MD: What an exciting time it is. In 2023, we have many more options and therapies. When we talk about biologics and some of our advanced therapies, we initially started with our anti–TNF [tumor necrosis factor] agents, but since then we have different and newer mechanisms of action [MOAs] over the past decades. It’s exciting to have different MOAs, different ways that we can treat with different biologics, whether it’s an antiadhesion, anti-interleukin, and now p19 antibodies. We also have oral small molecules. This is an example of the JAK inhibitors as well as our S1P. Each of these is approved for either Crohn disease or ulcerative colitis. It’s exciting because we’re finally able to tell our patients that when we open that medicine cabinet, we have more options than just that 1 biologic we started with in 1997.
David Hudesman, MD: It’s great for our patients.
Transcript edited for clarity.
